MicroQuin

🚀🌟 MicroQuin is the Cover Story of NASA & ISS Upward Magazine! 🌟🚀 We are beyond thrilled to share that MicroQuin has been featured as the cover story of NASA - National Aeronautics and Space Administration and International Space Station National Laboratory station #Upward magazine for December 2024! This incredible honor highlights our groundbreaking research and unwavering commitment to treating all cancers. 💡 Why This Matters: At MicroQuin, we are on a mission to revolutionize cancer treatment by targeting and eliminating cancer cells with precision and care. Our partnership with NASA has enabled us to leverage the unique environment of microgravity aboard the International Space Station (ISS) to explore innovative solutions that simply wouldn’t be possible on Earth. 🌍 A Global Impact: The insights gained from our work in space are already propelling us closer to transformative treatments that could change lives around the world. This milestone is not just a win for MicroQuin—it's a leap forward for science, healthcare, and humanity. 🎉 Thank You, NASA & ISS National Lab: We are deeply grateful to NASA, the ISS National Lab, and our incredible team of scientists, engineers, and supporters who believe in our vision. Together, we’re proving that the sky is not the limit—it's just the beginning. 🔗 Read the full story here: https://lnkd.in/e_gakTER Let’s keep reaching for the stars. 🌌 Together, we can achieve the extraordinary. #MicroQuin #NASA #ISS #CancerResearch #SpaceMedicine #Innovation #HealthcareTransformation

🔬 MicroQuin’s Breakthrough in Viral Treatment through TMBIM6 Research MicroQuin's mission is to pioneer transformative therapies by targeting cellular processes. Our latest research on TMBIM6 (formerly Bax Inhibitor-1) highlights its groundbreaking ability to regulate the intracellular environment (ICE) in response to stress, injury, and disease. What makes this discovery exciting? Viruses are essentially 'squatters' in the cell. Once inside, they hijack the cell to create the right IntraCellular Environment (ICE) so they can replicate and spread. What if you stop that from happening? ICE regulators, such as TMBIM6, can neutralize viral threats by stopping them hijacking the cell, while also protecting healthy cells. This innovative approach paves the way for unique and highly effective antiviral treatments. However, this breakthrough has far-reaching implications—not just for viral therapies, but also for tackling complex conditions like #neurodegenerative disorders and #cancer, where ICE changes play a critical role. At MicroQuin, we’re proud to push the boundaries of intracellular science, harnessing the power of molecular adaptability to develop treatments that make a meaningful difference in patients’ lives. #MicroQuin #CellularInnovation #TMBIM6 #AntiviralTherapies #Biotechnology #PrecisionMedicine

Forget Winter.... THE ICE AGE IS COMING! A recent publication in PNAS adds further support to the growing body of evidence that shows regulating the cells IntraCellular Environment (ICE) can have transformative outcomes for patients. Neurodegenerative diseases, such as #Parkinsons, induce ICE changes like Oxidative stress that are seen as the "heart of the disease". If you regulate ICE change you can transform patient outcome MicroQuin believe doctors have been right for decades... Using ICE can really help with #patient healing. The published work shows the neurotrophic factor mesencephalic astrocyte-derived neurotrophic factor (MANF) plays a critical role in maintaining cellular equilibrium. In doing so it impacts gene expression (via HLH-30/TFEB-mediated signalling) to regulate autophagy and lysosomal function. The authors go on to state that understanding MANF further could create #therapeutics that have huge implications for #parkinsonsdisease #alzheimersdisease #aging and age-related diseases. Article: https://lnkd.in/ggKsAk-Q

🔥 Game-Changer in Cancer Treatment! 🔥 MicroQuin published in Nature Oncogene (part of Nature Portfolio). Our article unveils the transformative power of TMBIM6 (formerly known as Bax Inhibitor-1) in treating #Cancer. We show TMBIM6 is an IntraCellular Environmental (ICE) regulator that unleashes paraptosis—a specialized cancer cell death—across all cancer types. Using ROS and calcium-driven pathways, TMBIM6 annihilates tumors without harming healthy cells. The best part? It's effective against even stubborn, chemoresistant cancers. Imagine harnessing this natural mechanism for safer, groundbreaking therapies. The future of oncology just got brighter! 🌟 #DisruptiveInnovation #CancerBreakthrough #OncologyRevolution #ScienceThatMatters The excitement doesn't stop there... regulating ICE can create treatments for #traumaticbraininjury #viralinfection #wounds #aging #parkinsonsdisease #alzheimersdisease and this is just the start HUGE THANKS to those who provided grant funding to progress this groundbreaking work: Boeing, International Space Station National Laboratory, and United States Department of Defense Article: https://lnkd.in/e7jStMJT

In October, we #thinkpink, and for a good reason—one out of every eight women will be diagnosed with #breastcancer in their lifetime, and each year, 2 million women are given this frightening diagnosis. 🎗️ #Biotechnology startup MicroQuin used the microgravity environment of space in an effort to learn how breast and prostate cancer cells develop and grow but "found something incredible that could lead to a way to treat not just breast and prostate cancers but all cancers." Details are in the latest issue of Upward, the official magazine of the ISS National Lab: https://ow.ly/T5L450TUVX2

🌌 Unveiling the Next ICE Age: Cellular Secrets to treating Disease and Injury Revealed in Space! ❄️ We’re excited to share MicroQuin’s results from our missions in space. In collaboration with NASA, our team leveraged the power of microgravity to develop revolutionary therapies that target cancer cells without harming healthy tissue. This groundbreaking research will not only change the future of oncology — but we have found a way to treat many of the world's top diseases and injuries. Check out how we’re pushing the limits of science in space! read more - https://lnkd.in/gbcEtNKT #CancerBreakthroughs #SpaceScience #MicroQuin #Oncology #neuro #treatment #startup #biotech #pharma

Stealth or just legally handcuffed? Startups, especially ones that are doing things no one else is, have a tough balancing act. What can we publicly say that doesnt hurt the IP we haven't filed yet, but shows everyone the magic inside the company. There is a need to build excitement, not just for funding purposes, but because you want to share your passion - especially when it is at the forefront of Science But the good news is MicroQuin's handcuffs are about to come off and we cannot wait to shout about our work! #startup #biotechnology #pharma #drug #drugdiscovery

“No one changes the world who isn’t obsessed.” - Billie Jean King It is that 'obsessive drive' our scientific founder Scott Robinson, PhD, CQF has, which resulted in a new concept for disease/injury treatment. The idea that Intracellular Environmental (ICE) change is at the core of disease and injury progression, and that regulating ICE change can transform disease outcome. Furthermore, even natural processes (i.e., aging) can be slowed or reversed with by regulating ICE change. A scientifically obvious idea, yet one that was regularly refused grant funding. Undeterred Dr Robinson left the lab bench to for investment banking so he could fund the research himself and pay other scientists to assess the validity of this idea. Once enough data showed, beyond reasonable doubt, that regulating ICE change could transform disease treatment MicroQuin was born. An unusual story, so much so the Boston Globe wrote an article about it, of how one person's drive and love for Science can overcome any obstacle - even funding issues. https://lnkd.in/epp3r8Ac

We are extremely pleased to welcome another phenomenal expert to the MicroQuin team. Dr. Peter Sennhenn is a medicinal chemist, small molecule drug hunter and biotech entrepreneur with 30 years of experience in pharmaceutical and biotech industry where he led several medicinal chemistry departments and managed multidisciplinary project teams and discovery programs. Peter got his PhD in organic chemistry from the University of Heidelberg (summa cum laude), followed by postdoctoral studies at the Scripps Institute with two-time Nobel laureate K. Barry Sharpless. After 10 years at Boehringer Ingelheim in Germany and Austria as a lab and group leader, he built up and headed the medicinal chemistry departments at GPC biotech, Proteros and Bioversys. In 2012, he founded transMedChem Consulting, a preclinical drug discovery consulting company, through which he has supported more than 50 startup and biotech companies in Europe, the US and Asia to advance their drug discovery projects from hit to lead to candidate stage and enabled the identification of multiple clinical drugs. Dr. Sennhenn is a member of the German, Swiss and American Chemical Society. 

🔬 Unlocking the Power of Regulating the Intracellular Environment 🔬 MicroQuin has achieved several exciting breakthroughs over the last quarter, which could reshape our understanding of new types of cell death and disease treatment by regulating the intracellular environment! 💡 To start... We are looking for cell death academics who wish to #collaborate to advance mankind's understanding of #paraptosis. Please reach out at info@microquin.com #IntracellularRegulation #microquin #celldeath #Biotechnology #PrecisionMedicine #DiseaseCure #Innovation 🔬💊